NCT02929485

Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of California, Berkeley · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

In this study, the investigators are looking at how people make decisions about reward-related items, both monetary and food related after taking either the dopamine agonist bromocriptine or the COMT inhibitor tolcapone, in healthy control subjects. Subjects will fill self-report questionnaires and undergo an MRI scan.

Detailed description

The investigators aim to understand how the brain's dopamine system impacts monetary and food-related decision making. The investigators aim to use tolcapone and bromocriptine due to the temporary change in the levels of dopamine in the brain. The investigators also aim to determine if genetics, personality traits, or a family history of alcoholism change how these drugs affect decision making.

Conditions

• Addiction

Interventions

Type	Name	Description
DRUG	Tolcapone	Tolcapone 200mg (single dose) administered at study visit
DRUG	Placebo	Placebo (200mg) administered at study visit
DRUG	Bromocriptine	Drug: Bromocriptine 1.25 mg (single dose) administered at study visit

Timeline

• Start date: 2013-07-01
• Primary completion: 2018-01-31
• Completion: 2018-01-31
• First posted: 2016-10-11
• Last updated: 2021-11-16

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study